To further demonstrate the therapeutic potentials of targeting KDM4C in AML, we tested the leukemia inhibitory activity of a newly developed KDM4C inhibitor, SD70 (Jin et al., 2014). The gene discussed is KDM4C; the disease is acute myeloid leukemia.